Inspire HGNS denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for inspire hgns are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied the Inspire HGNS System as Duplicate Therapy — and Why You Can Appeal

Cigna may issue a duplicate-therapy denial when it determines that a proposed treatment serves the same clinical purpose as one already being covered or recently used. For the Inspire Hypoglossal Nerve Stimulation system — an implantable neurostimulator for obstructive sleep apnea (OSA) — this denial most often arises when positive airway pressure (PAP) therapy is still active on the patient's account, or when a prior surgical procedure for OSA was coded in a way that appeared to overlap with the device's function. The insurer's algorithm flags the two as redundant.

This denial is routinely overturned on appeal because the Inspire device is indicated specifically for patients who cannot adequately use PAP therapy. The two are not duplicates — they are sequentially appropriate therapies at different stages of the care pathway. A clear clinical narrative corrects the misclassification.

## Federal Appeal Rights

ACA §2719 requires non-grandfathered plans to provide at least two internal appeal levels and independent external review. ERISA §503 guarantees full-and-fair review for employer-plan participants. The external-review window is typically 180 days from your denial notice — confirm the exact date on your Explanation of Benefits. Expedited review (decision within roughly 72 hours) is available when your health would be seriously jeopardized by the standard timeline.

## Concrete Appeal Process

1. Request the complete denial rationale and Cigna's coverage policy for hypoglossal nerve stimulation, identifying exactly which existing therapy Cigna considers duplicative. 2. File a Level 1 internal appeal. The central argument is distinction: explain why PAP therapy (or any prior OSA procedure) is clinically separate from, not duplicative of, the Inspire system — citing the specific reason PAP was discontinued or is contraindicated. 3. If denied, file a Level 2 internal appeal with additional specialist support, then proceed to independent external review.

## Documentation to Gather

• Diagnosis confirmation: Current polysomnography documenting active, clinically significant OSA.
• PAP-therapy history: Records showing when PAP was prescribed, objective adherence data, and the dated clinical decision to discontinue it — establishing a clear break in therapy.
• Clinical distinction statement: A physician letter explicitly explaining why the Inspire device addresses a need that PAP or prior surgery did not and cannot meet.
• Prescriber medical-necessity letter: Ties the clinical narrative to Cigna's published coverage criteria for the device, addressing each criterion individually.
• Prior authorization records: If a prior OSA procedure was the alleged duplicate, include operative notes showing it targeted a different anatomical structure or mechanism.

## Criteria-Mapping Structure

Obtain Cigna's current medical coverage policy for hypoglossal nerve stimulation and list each coverage criterion. For each one, provide the matching chart fact and date. Then add a separate section titled "Why This Is Not Duplicate Therapy" that addresses, point by point, the specific therapy Cigna identified and explains the clinical distinction. This reframes the appeal from a general medical-necessity argument to a precise rebuttal of the duplicate-therapy rationale.